BeOne Medicines Files 2025 Form 10-K, Underscoring Cross-Border Compliance

BeOne Medicines Ltd ( (HK:6160) ) just unveiled an announcement.

BeOne Medicines Ltd has announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The filing confirms the company’s status as a large accelerated filer, its compliance with U.S. reporting and internal control requirements, and provides updated disclosure for investors across its Nasdaq, Hong Kong and STAR Market listings.

The announcement, made in Hong Kong under the city’s listing rules, underscores BeOne Medicines’ obligations as a cross-border issuer and its adherence to parallel regulatory regimes in the United States and Hong Kong. With a non-affiliate market capitalization of about $14.7 billion as of June 30, 2025, the company’s continued timely reporting and control attestation are likely to be closely watched by global shareholders and regulators.

The most recent analyst rating on (HK:6160) stock is a Buy with a HK$290.00 price target. To see the full list of analyst forecasts on BeOne Medicines Ltd stock, see the HK:6160 Stock Forecast page.

More about BeOne Medicines Ltd

BeOne Medicines Ltd is a Switzerland-incorporated biopharmaceutical company whose securities trade in multiple markets, including American Depositary Shares on the Nasdaq Global Select Market and ordinary shares on the Hong Kong Stock Exchange. The company also has RMB-denominated shares listed on China’s STAR Market, though these are not fungible with its Hong Kong-listed ordinary shares or U.S.-listed ADSs.

Average Trading Volume: 3,313,309

Technical Sentiment Signal: Buy

Current Market Cap: HK$348B

Learn more about 6160 stock on TipRanks’ Stock Analysis page.